Biotech Values

[nymup]

SGMO - Wasn't there a European trial a few years back that set back gene therapy because of leukemia in some patients?

Yes, the problem was that they used a viral vector to modify the DNA. Not enough specificity. SGMO is getting close to clinical trials in HIV that will once again attempt DNA modification. In this case, the modifications will be performed by SGMO's Zinc Finger Proteins (ZFPs) that can precisely target the exact spot where the modification is to occur. They also use a viral vector, but only to get the ZFPs into the cell. The virus isn't involved in the DNA modifications. The link below describes their current status.

http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-newsArticle&t=Regular&id=90983...